fashion -WSS

fashion

author：entertainment 2025-09-28 23:11:29 - browse：387

Eli Lilly headquarters — Kristoffer Tripplaar/AP

Eventually, the luckiest companies get to deal with a very particular problem: what to do when their stock could be getting ahead of itself.

It’s a problem Eli Lilly got a little taste of Tuesday when it announced its full-year earnings. The drugmaker’s stock has more than doubled over the past 12 months due to the ever-increasing hopes for its GLP-1-based diabetes and weight loss drug, sold under the brand names Mounjaro and Zepbound. It was a big deal when Lilly became the first drug company ever to have a market value of $500 billion; it’s now sitting at a stunning $670 billion.

At first, the earnings report suggested the company had blasted through expectations again, announcing fourth-quarter 2023 sales of $9.35 billion, almost half a billion dollars above analysts’ expectations, and also announcing new data for Mounjaro in treating metabolic dysfunction-associated steatohepatitis (MASH), a form of liver disease previously called NASH. Initially, shares traded up 5%.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Feed a cold, starve a fever? Here’s what science says

WSS

Oral obesity drug from Viking Therapeutics hits key early target

Florida Supreme Court upholds state's abortion ban

Election results set back Medicaid expansion plans

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

Researchers test human milk's ability to repair gut microbiome

Doctors push to include dialysis machines in emergency stockpile

knowledge

fashion

hotspot

Walensky prepares to leave CDC — and Congress — behind

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast

DIEP, the 'gold standard' of breast reconstruction, is under threat

Pennsylvania man bitten on the head by bear during attack in his garage

Activists slam private health insurers over coverage restrictions

Trial using CRISPR to edit HIV out of cells disappoints

Hollywood unions extend contract negotiations for actors

UnitedHealth, in a surprise, takes aim at Steward’s physician group

What does generative AI mean for health care? We asked experts

Sage considers ways to reduce costs following FDA rejection

Wikipedia

Failure, not just success, should guide future doctors

Insurer loopholes limit power of law against surprise medical bills

How CRISPR works, explained in two minutes

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Sage considers ways to reduce costs following FDA rejection

Overprescribed: High cost isn't America's only drug problem

explore

focus

hotspot

hotspot